
A large, international analysis of patients with stage IV non-small cell lung cancer (NSCLC) indicates that a patient’s overall survival (OS) rate can be related to factors including the timing of when metastases develop and lymph node involvement, and that aggressive treatment for “low-risk” patients leads to a five-year OS rate of 47.8 percent, according to new research.
http://feeds.sciencedaily.com/~r/sciencedaily/~3/WlxvMBZgOzQ/140916101810.htm